Clinical trials: Hepatocellular Carcinoma Metastatic
Neoplastic Disease, Solid Tumor
Indocyanine Green (ICG) Guided Tumor Resection
This is a study to assess the ability of Indocyanine Green (ICG) to identify neoplastic disease. For many pediatric solid tumors, complete resection of the primary site and/or metastatic deposits is critical for achieving a cure.
- Trial name
- NCT04084067
- Testing
- Indocyanine Green
- Where
- United States
- Volunteers
- 215 people
- Sponsor
- St. Jude Children's Research Hospital
Liver Tumors
Freehand Ultrasound Elasticity Imaging in Liver Surgery
The purpose of this study is to investigate the potential for visualizing radiofrequency-induced (RFA) and microwave-induced (MWA) hepatic thermal ablation lesions using a novel, high resolution, and freehand ultrasound…
- Trial name
- IOUS (NCT00942383)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hepatocellular Carcinoma (HCC)
Regional Lymph Node Metastasis and Survival Outcomes in Advanced HCC
Tumor-draining lymph nodes play an important role in anti-tumor immune responses. In patients with hepatocellular carcinoma (HCC), however, the relationship between regional lymph node metastasis (LNM) and immunotherapy-based…
- Trial name
- CHANCE2421 (NCT06876753)
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Zhongda Hospital
Hepatocellular Carcinoma, Metastasis
Radiofrequency Ablation Using Octopus Electrodes for Treatment of Focal Liver Malignancies
The purpose of this study is to evaluate the clinical feasibility and short-term outcome of switching monopolar RFA using a separable cluster electrode in patients with primary and secondary liver malignancies.
- Conditions
- Hepatocellular Carcinoma, Metastasis, Cholangiocarcinoma
- Trial name
- NCT02683538
- Testing
- Separable cluster electrode (Octopus®)
- Where
- South Korea
- Volunteers
- 196 people
- Sponsor
- Seoul National University Hospital
Hepatocellular Carcinoma, Colorectal Cancer Liver Metastasis
The Safety, Efficacy, and Immune Response of Multimodal Thermal Therapy in the Treatment of Malignant Liver Tumors
Multimodal thermal therapy (MTT), as an initiative integration of cryotherapy and radiofrequency heating, has been applied to treat various solid tumors.
- Trial name
- NCT07159048
- Testing
- Multimodal Tumor Thermal Therapy System, Radiofrequency Ablation System or Microwave Ablation System
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fudan University
Patients With Resectable Hepatocellular Carcinoma Who Are at High Risk of Recurrence or Metastasi
TQB2450 Combined With Anlotinib Hydrochloride in the Perioperative Treatment of Hepatocellular Carcinoma Hydrochloride Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With a High Risk of Recurrence or Metastasis
In this study, single cell transcriptome sequencing will be performed on the tissue samples punctured and the surgically resected specimens to explore the gene mutation sites related to efficacy
- Trial name
- NCT04888546
- Testing
- Anlotinib hydrochloride capsules＋ TQB2450 injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese Academy of Medical Sciences
Advanced Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer
Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
open-label trial of an allogeneic dual-target CAR-NK product directed against GPC3 and B7-H3 for adults with advanced hepatocellular carcinoma.
- Trial name
- DUET-HCC (NCT07500220)
- Testing
- EB-G3B7-NK dual-target CAR-NK cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Biotech
Carcinoma, Hepatocellular, Metastatic Colorectal Cancer
Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies
This is a pilot, open label single arm phase 0 window of opportunity study of vandetanib-eluting radiopaque beads in patients with resectable liver malignancies.
- Trial name
- VEROnA (NCT03291379)
- Testing
- BTG-002814
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- Boston Scientific Corporation
Hepatocellular Carcinoma
SynOV1.1 Intratumoral Injection Study
This is a Phase I, open-label, multicenter study to characterize safety and tolerability, evaluate biodistribution, biological effects and immunogenicity, and evaluate the preliminary clinical efficacy of SynOV1.1 in participants…
- Trial name
- NCT04612504
- Testing
- SynOV1.1
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Beijing Syngentech Co., Ltd.
Hepatocellular Carcinoma (HCC)
Role of Long Noncoding RNA LINC01134 in Metastasis of Hepatitis C Virus-related Hepatocellular Carcinoma
LINC01134, a novel lncRNA, has received increasing attention in cancer research, particularly in hepatocellular carcinoma (HCC).
- Trial name
- NCT07130474
- Volunteers
- 50 people
- Sponsor
- Sohag University
Hepatocellular Carcinoma (HCC), Metastasis
Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases
This study will evaluate whether resection of the primary liver tumor, in addition to standard first-line systemic therapy, improves survival in patients with hepatocellular carcinoma that has spread outside the liver but still…
- Trial name
- NCT07537959
- Testing
- Primary Tumor Resection, Protocol-Allowed First-Line Immune-Based Systemic Therapy
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma
Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular Carcinoma
The investigators design a phase II clinical study to explore the efficacy and safety of Transarterial Chemoembolization (TACE) + Lenvatinib + Icaritin soft capsules in patients with Unresectable, non-metastatic hepatocellular…
- Trial name
- NCT05903456
- Testing
- TACE（transcatheter arterial chemoembolization）, lenvatinib, Icaritin soft capsules
- Volunteers
- 20 people
- Sponsor
- Zhejiang Cancer Hospital
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine, epirubicin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer
- Trial name
- NCT00486356
- Testing
- capecitabine, carboplatin, epirubicin hydrochloride
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Nebraska
Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer
This phase II trial tests how well the combination of celecoxib with durvalaumab and tremellimumab works in treating patients with hepatocellular cancer (liver cancer) that may have spread from where it first started to nearby…
- Conditions
- Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT07174570
- Testing
- Celecoxib, Durvalumab, Tremelimumab
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- Emory University
Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma
Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer
This phase II trial investigates the effect of combining two immune therapies, atezolizumab and CDX-1127 (varlilumab), with or without cobimetinib, in treating patients with biliary tract cancer that cannot be removed by surgery…
- Conditions
- Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Recurrent Distal Bile Duct Adenocarcinoma
- Trial name
- NCT04941287
- Testing
- Atezolizumab, Biopsy, Biospecimen Collection
- Where
- 29 sites in United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma (HCC)
A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma
This is a multicenter, open-label, dose-escalation study designed to determine the maximum tolerated dose (MTD) by evaluating dose-limiting toxicities (DLTs) and to evaluate the safety, tolerability, pharmacokinetics, anti-tumor…
- Trial name
- NCT05022927
- Testing
- ERY974, Tocilicumab, Atezolizumab
- Where
- 11 sites in Japan, Taiwan
- Volunteers
- 179 people
- Sponsor
- Chugai Pharmaceutical
Solid Cancer
A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed
The purpose of this study is to enable participants, currently receiving regorafenib in a Bayer-sponsored clinical trial, to continue treatment after their respective study has been closed.
- Trial name
- NCT03890731
- Testing
- BAY73-4506 (Regorafenib, Stivarga)
- Where
- 6 sites in United States, Germany and 3 more
- Volunteers
- 6 people
- Sponsor
- Bayer
Hepatocellular Carcinoma
A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma
This study will evaluate the safety, tolerability, pharmacokinetic and efficacy of fisogatinib (formerly known as BLU-554) in combination with CS1001 in patients with locally advanced or metastatic hepatocellular carcinoma (HCC)
- Trial name
- NCT04194801
- Testing
- Phase Ib: Fisogatinib (BLU-554) 400mg in combination with Sugemalimab (CS1001) 1200mg, Phase Ib: Fisogatinib (BLU-554) 600mg in combination with Sugemalimab (CS1001) 1200mg, Phase II: Fisogatinib (BLU-554) 600mg in combination with Sugemalimab (CS1001) 1200mg
- Where
- 3 sites in China
- Volunteers
- 26 people
- Sponsor
- CStone Pharmaceuticals
Hepatocellular Carcinoma, Hilar Cholangiocarcinoma
Optimization of Health Expenditure in Liver Surgery
The aim of this study is to reduce the length of stay after liver surgery by taking account of objective quantitative clinical variables, subjective qualitative clinical variables and non clinical variables.
- Conditions
- Hepatocellular Carcinoma, Hilar Cholangiocarcinoma, Intra Hepatic Cholangiocarcinoma, Liver Metastasis
- Trial name
- NCT01715402
- Testing
- liver surgery
- Where
- 11 sites in France
- Volunteers
- 3,000 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Metastatic Hepatocellular Carcinoma, HCC
Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC)
This single arm, open label, two stage study will be conducted in several medical centers around Taiwan. Stage one determine safety and tolerability in patients with HCC, and stage two assess anti-tumor activities of GT90001 in…
- Conditions
- Metastatic Hepatocellular Carcinoma, HCC, Combinations of Drugs; Dependence
- Trial name
- NCT03893695
- Testing
- GT90001 and Nivolumab
- Where
- 3 sites in Taiwan
- Volunteers
- 20 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,